International Stem Cell (ISCO) reported Q119 revenues of $2.2m, down 15.8% compared with Q118 as both the biomedical and cosmetic businesses exhibited weakness. Biomedical revenues, which had been up 78.4% in 2018, were down 16.2% for the quarter. The profitability of the biomedical business also declined as revenues fell but expenses grew. The segment provided $0.8m in profits in Q118, but only $0.3m this quarter.
05 Jun 2019
International Stem Cell - Q119 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
International Stem Cell - Q119 results
- Published:
05 Jun 2019 -
Author:
Maxim Jacobs -
Pages:
5
International Stem Cell (ISCO) reported Q119 revenues of $2.2m, down 15.8% compared with Q118 as both the biomedical and cosmetic businesses exhibited weakness. Biomedical revenues, which had been up 78.4% in 2018, were down 16.2% for the quarter. The profitability of the biomedical business also declined as revenues fell but expenses grew. The segment provided $0.8m in profits in Q118, but only $0.3m this quarter.